<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hepatitis C and alcohol
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hepatitis C and alcohol
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hepatitis C and alcohol
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher A Marshall, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjiv Chopra, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gyongyi Szabo, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keith D Lindor, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allyson Bloom, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 13, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic hepatitis C virus (HCV) and alcohol are common causes of chronic liver diseases in the United States, and both are recognized as major causes of liver disease worldwide [
         <a href="#rid1">
          1
         </a>
         ]. Each poses a major public and economic burden to society, and when the two coexist they appear to have a synergistic effect in the progression of chronic liver disease.
        </p>
        <p>
         This topic will review the effect of alcohol on the natural history and treatment of hepatitis C. Other issues related to hepatitis C and alcohol-associated liver disease are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3675.html" rel="external">
          "Epidemiology and transmission of hepatitis C virus infection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">
          "Screening and diagnosis of chronic hepatitis C virus infection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3672.html" rel="external">
          "Clinical manifestations and natural history of chronic hepatitis C virus infection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3673.html" rel="external">
          "Overview of the management of chronic hepatitis C virus infection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3650.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3613.html" rel="external">
          "Pathogenesis of alcohol-associated liver disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3617.html" rel="external">
          "Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3611.html" rel="external">
          "Management of alcohol-associated steatosis and alcohol-associated cirrhosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY OF HEPATITIS C IN PATIENTS WITH AN ALCOHOL USE DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of HCV infection in patients with a history of alcohol abuse is significantly higher than that seen in the general population. Initial reports that were based upon first-generation enzyme-linked immunosorbent assays documented a prevalence of HCV antibodies as high as 45 percent [
         <a href="#rid2">
          2,3
         </a>
         ]. Subsequent studies that used more accurate tests like recombinant immunoblot assays (RIBA-I, RIBA-II) and polymerase chain reaction (PCR) found a lower prevalence (14 to 36 percent), but still substantially increased compared to the general population [
         <a href="#rid4">
          4-8
         </a>
         ]. The prevalence of HCV among patients hospitalized with alcohol-related disorders is also increased (15 percent in one report) [
         <a href="#rid9">
          9
         </a>
         ]. In a study of US veterans with hepatitis C, 44 percent had a history of alcohol abuse or dependence [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The reason for the higher incidence of HCV infection among those with an alcohol use disorder is incompletely understood. An increased prevalence of high-risk behaviors (such as intravenous drug abuse) among patients with an alcohol use disorder has been observed in some reports [
         <a href="#rid11">
          11-13
         </a>
         ], although others have not detected this association [
         <a href="#rid14">
          14,15
         </a>
         ]. Most of the studies did not address other potential risk factors, such as cocaine snorting, tattoos, body piercing, and a history of sexually transmitted diseases. Understanding of hepatitis C epidemiology remains elusive and there is a need to improve the tools used to measure practices that can be associated with HCV transmission and are not usually volunteered [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EFFECT OF ALCOHOL ON THE NATURAL HISTORY OF HEPATITIS C
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have focused on identifying how alcohol affects the natural history of HCV and liver disease. Three observations have emerged from an increasing body of data on alcohol consumption in patients with chronic HCV. Heavy alcohol use:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Accelerates fibrosis progression and increases the risk of cirrhosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Predicts increased mortality
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increases the risk of hepatocellular carcinoma
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Acceleration of fibrosis and cirrhosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A consistent observation has been that patients who are infected with hepatitis C and consume alcohol are at increased risk for progression to cirrhosis [
         <a href="#rid18">
          18-28
         </a>
         ]. An illustrative study included 2235 patients with chronic hepatitis C in whom three independent factors were associated with increased rate of fibrosis progression [
         <a href="#rid18">
          18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age at infection (older than 40 years)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Male sex
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Daily alcohol consumption of 50 g or more
        </p>
        <p>
        </p>
        <p>
         Daily alcohol consumption of 50 g or greater was associated with a 34 percent increase in the rate of fibrosis progression, which was defined as the ratio between the histological fibrosis stage (five-point scale: 0 = no fibrosis to 4 = cirrhosis) and the estimated duration of infection in years. Other potential risk factors, such as the genotype, quantity of HCV RNA, and mode of acquisition of hepatitis C infection, were not associated with higher fibrosis progression. A standard drink contains 12 g of alcohol and is equivalent to 360 mL (12 oz) of beer, 150 mL (5 oz) of wine, or 45 mL (1.5 oz) of whiskey or other 80 proof distilled spirits.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar conclusions were reached in another report that focused on 1667 HCV-positive injection drug users who were followed for a median of nine years [
         <a href="#rid27">
          27
         </a>
         ]. The relative risk of end-stage liver disease was increased almost fourfold for those who drank more than 260 g of alcohol per week (RR 3.6, 95% CI 1.73 to 7.52).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis pooled data from 16 studies involving more than 15,000 patients looking at the impact of alcohol on those with HCV. With regard to the combined outcome (cirrhosis or decompensated cirrhosis), heavy alcohol use (&gt;240 to 560 g/week) was associated with an increased risk when compared to those with less than heavy use (RR 2.33, 95% CI 1.67-3.26) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study of United States veterans compared with non-veterans with hepatitis C infection found that veterans were older and had higher lifetime alcohol consumption than non-veterans, but their median fibrosis scores did not differ from non-veterans [
         <a href="#rid30">
          30
         </a>
         ]. However, fibrosis in non-veterans was significantly associated with increased alcohol consumption (men &gt;150 kg lifetime: four to five drinks per day for &gt;10 years; women &gt;100 kg lifetime: &gt;3 drinks per day for &gt;10 years) [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The exact amount of alcohol that increases the risk of HCC in patients with HCV is unknown but it appears that even modest alcohol use can accelerate fibrosis [
         <a href="#rid31">
          31
         </a>
         ]. This was illustrated in a study of 800 patients with HCV who underwent liver biopsies and in whom a detailed alcohol history was assessed. A spectrum of fibrosis was observed for each category of alcohol intake (none, light, moderate, and heavy).
        </p>
        <p>
         Another study of 3404 newly referred patients with hepatitis C identified factors associated with severe liver disease (ie, cirrhosis or liver cancer) [
         <a href="#rid32">
          32
         </a>
         ]. Patients with severe liver disease were more likely to have past excessive alcohol consumption defined as &gt;21 glasses per week for women, &gt;28 glasses per week for men (adjusted OR 2.6, 95% CI 1.9-3.5). While this observation was significant in those with &gt;5 years of excessive alcohol use, it was not seen in those with &lt;5 years of excessive alcohol use.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Increase in mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Concomitant alcohol abuse has been associated with increased mortality in patients with HCV [
         <a href="#rid28">
          28,33-35
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study in a referral center found significantly increased five-year mortality in patients with HCV and alcohol abuse compared with HCV alone (28 versus 10 percent) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study evaluated more than 7 million death records in the United States from 2000 to 2002 [
         <a href="#rid34">
          34
         </a>
         ]. Patients were categorized as having HCV without heavy alcohol use (HAU), HAU without HCV, HCV plus HAU, and all others. Among men, those with HAU and HCV had a significantly lower mean age of death when compared with those with HCV alone (50 versus 55 years). A similar observation was seen in women (49 versus 61 years).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Risk of hepatocellular carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         A growing number of studies have demonstrated that patients with alcohol-associated liver disease who are infected with HCV are at increased risk for the development of hepatocellular carcinoma (HCC) compared with those with HCV alone [
         <a href="#rid36">
          36-42
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3599.html" rel="external">
          "Epidemiology and risk factors for hepatocellular carcinoma"
         </a>
         ). The mechanisms underlying this interaction are poorly understood. The following examples illustrate the range of findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A case control study included 305 patients with newly diagnosed HCC (of whom 122 were HCV RNA positive) who were compared to 610 controls without liver disease [
         <a href="#rid38">
          38
         </a>
         ]. The risk of HCC was increased 26-fold in patients who were HCV RNA positive (Odds ratio 26.3, 95% CI 15.8 to 44). The risk was increased 126-fold among patients who were HCV RNA positive who consumed more than 80 g/day of alcohol (Odds ratio 126, 95% CI 42.8 to 373). An additional finding from this study was an increased risk of HCC in patients with concomitant infection with hepatitis B (Odds ratio 132, 95% CI 15.3 to 54.0), a finding that has been confirmed in several other studies [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective cohort study included 290 consecutive patients with cirrhosis (69 percent of whom were positive for HCV antibodies) who were followed with periodic ultrasound examinations [
         <a href="#rid40">
          40
         </a>
         ]. During an average follow-up of 46 months, HCC developed in 32 patients (11 percent), including 20 percent of those who were HBsAg positive, 12 percent of those who were HCV antibody positive, and 14 percent of those with a history of alcohol abuse. On multivariate analysis, independent predictors of the development of HCC included positivity for HBsAg and HCV antibodies, male sex, and alcohol abuse. These results were comparable to an earlier prospective study with a similar design [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A case-control study included 115 cases who were compared with 230 controls with non-liver cancer [
         <a href="#rid42">
          42
         </a>
         ]. On multivariate analysis, independent predictors of HCC included antibodies against HCV or HBV, heavy alcohol consumption, and diabetes mellitus. The risk appeared to be synergistic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one small study, bile duct dysplasia was found to be associated with chronic HCV and alcohol cirrhosis. Of 19 cases of dysplasia, 19 were in the setting of HCV and 4 out of 19 were in the setting of combined HCV and alcohol use [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          PATHOGENESIS OF ACCELERATED INJURY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanisms underlying the interaction between alcohol, hepatitis C, and liver disease are incompletely understood and are likely beyond that of just additive injury. There are several theories regarding the interaction of alcohol and hepatitis C  (
         <a class="graphic graphic_algorithm graphicRef65942" href="/z/d/graphic/65942.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol increases HCV replication
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol and HCV affect host cellular immunity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol and HCV increase oxidative stress
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol increases HCV quasispecies
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Effect of alcohol on HCV replication
         </span>
         <span class="headingEndMark">
          —
         </span>
         One possible explanation for worsened outcome in alcohol consuming patients is that alcohol may increase HCV replication. Several in vitro studies have demonstrated upregulation of HCV replication (about a threefold increase at 96 hours) and protein expression in cells treated in an alcohol rich environment [
         <a href="#rid44">
          44-46
         </a>
         ]. Disparate data have also been published, although differences in experimental techniques may have accounted for the varying results [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Several studies have also suggested that HCV RNA is increased in drinkers compared with nondrinkers [
         <a href="#rid10">
          10,18,30,48
         </a>
         ]. However, the strength of this association is unclear. A meta-analysis of 14 studies found no significant association between HCV RNA levels and the amount of alcohol consumption [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         Other authors have looked at the acute effect of alcohol on HCV levels in patients. One such report included 21 patients with chronic hepatitis C who were randomly assigned to receive a single dose of alcohol (50 g) versus placebo [
         <a href="#rid50">
          50
         </a>
         ]. No significant effects on HCV RNA were detected.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Alcohol affects host cellular immunity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have evaluated the interaction of HCV and alcohol on host cellular immunity [
         <a href="#rid47">
          47,51-55
         </a>
         ]. The following general observations have been made:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol influences hepatocyte transduction pathways possibly acting with HCV to induce alterations in cellular responses to HCV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Host dendritic cells are modulated by HCV infection and by alcohol. The presence of HCV proteins (core and NS3) reduced dendritic cell differentiation in vitro while alcohol further reduced dendritic cell function by decreasing T cell stimulation and interferon production [
         <a href="#rid53">
          53,55
         </a>
         ]. These effects inhibited the antiviral response. Animal models of long-term alcohol consumption have also demonstrated an impaired cellular immune response to HCV infection attributable to altered dendritic cell function [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of alcohol inhibits the antiviral actions of exogenous interferon [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol consumption did not influence T cell immune responses (interferon gamma and IL-10 production) in HCV or HCV/HIV coinfected patients [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Alcohol and HCV increase oxidative stress
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alcohol intake increases oxidative stress in patients with HCV. An illustrative study compared measures of oxidative stress in 145 patients with chronic hepatitis C virus, 20 heavy drinkers without HCV, and 50 controls [
         <a href="#rid56">
          56
         </a>
         ]. The risk of developing oxidative stress during chronic hepatitis C infection was increased threefold by moderate alcohol intake (&lt;50gm ethanol/day) and 13- to 24-fold in chronic hepatitis C patients with heavy alcohol intake (&gt;50 gm ethanol/day). The authors conclude that HCV and alcohol act synergistically in stimulating free radical generation as well affecting antioxidant defenses.
        </p>
        <p>
         In vivo observations are further confirmed with in vitro studies. In studies of hepatoma cells, HCV protein, enhanced CYP2E1 expression, and alcohol acted synergistically to enhance reactive oxygen species and sensitize cells to mitochondrial depolarization and cell death by TNF or oxidative stress [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         HCV alters the redox state of hepatocytes leading to changes in mitochondrial structure and function. As an example, the HCV NS5a protein appears to contribute to development of reactive oxygen species in mitochondria and endoplasmic reticulum (ER). HCV core protein induces ER stress, an effect exacerbated by alcohol, thereby further oxidizing the mitochondrial antioxidant (glutathione) pool [
         <a href="#rid58">
          58
         </a>
         ]. Oxidative stress may contribute to liver injury and impair liver regeneration [
         <a href="#rid56">
          56,59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Alcohol increases HCV quasispecies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatitis C exists as closely related "quasispecies". Alcohol increases the diversity of HCV quasispecies by mechanisms that are poorly understood. One theory is that the generation of reactive oxygen species (see above) increases the mutation rate of the HCV genome, thereby driving viral evolution [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         However, the clinical implications of alcohol and HCV quasispecies diversification are unclear. On the one hand, increased quasispecies complexity has been associated with poor responsiveness to interferon-alfa, possibly contributing to the decreased responsiveness of patients with an alcohol use disorder and HCV to interferon treatment [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="local">
          'Effect of alcohol on treatment of hepatitis C'
         </a>
         below.)
        </p>
        <p>
         On the other hand, low quasispecies diversification has been associated with more severe disease [
         <a href="#rid62">
          62
         </a>
         ]. This may reflect immune failure and/or selective outgrowth of aggressive viral variants. In one such report, alcohol had no significant association between the degree of quasispecies diversification and the severity of liver disease [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          HISTOPATHOLOGIC CORRELATES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Liver histology in patients with alcohol-associated liver disease and HCV may demonstrate the typical histologic features of alcohol-associated liver disease, such as macrovesicular steatosis, polymorphonuclear infiltrate, hepatocyte ballooning, and Mallory bodies. Superimposed features of chronic hepatitis, such as periportal necrosis, portal inflammation, lymphoid aggregates in the portal tracts, and lymphocytosis in the sinusoids, are also commonly present [
         <a href="#rid14">
          14,63,64
         </a>
         ]. As expected, there is a higher risk of fibrosis seen in consumers of alcohol (&gt;50 g/day) versus those with lower intakes of alcohol on liver biopsy  (
         <a class="graphic graphic_figure graphicRef61200" href="/z/d/graphic/61200.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Acceleration of fibrosis and cirrhosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          EFFECT OF ALCOHOL ON TREATMENT OF HEPATITIS C
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the advent of new oral direct-acting antiviral (DAA) combination therapy for HCV treatment, HCV eradication became a reality for most patients, regardless of HCV genotype or liver fibrosis stage. Clinical studies that defined the current doses and lengths of effective HCV DAA therapies required no or negligible alcohol use during treatment. Thus, to date, there are no data as to how the oral anti-HCV therapies would perform in patients with ongoing alcohol use [
         <a href="#rid65">
          65
         </a>
         ]. Given that the action of the serine protease inhibitors involves enabling the host endogenous type I interferon pathways that can be inhibited by alcohol use itself, patients most likely should avoid alcohol use during anti-HCV therapy, even with the new oral agents.
        </p>
        <p>
         Ongoing alcohol use decreases the efficacy of interferon-based treatment of HCV [
         <a href="#rid44">
          44,48,66,67
         </a>
         ]. The reason for the decreased responsiveness is incompletely understood. It may in part be due to decreased compliance, although several biological mechanisms have also been hypothesized, such as potentiation of HCV replication [
         <a href="#rid44">
          44,45,68,69
         </a>
         ]. (See
         <a class="local">
          'Pathogenesis of accelerated injury'
         </a>
         above.)
        </p>
        <p>
         By contrast, data regarding the impact of past alcohol use (more than six months prior to therapy) are conflicting. Considered together, the studies suggest that past alcohol use has no impact on treatment [
         <a href="#rid68">
          68,70-72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          HOW MUCH ALCOHOL IS TOO MUCH?
         </span>
         <span class="headingEndMark">
          —
         </span>
         The amount of alcohol required to increase the risk of disease progression in patients with HCV has not been well defined. Although most of the studies discussed above included patients with alcohol intake of &gt;50 g/day, more modest alcohol intake (&lt;140 g/week) has been associated with increased HCV viremia and hepatic fibrosis [
         <a href="#rid21">
          21
         </a>
         ]. Even modest alcohol intake is associated with increased oxidative stress [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         A standard drink contains 12 g of alcohol and is equivalent to 360 mL (12 oz) of beer, 150 mL (5 oz) of wine, and 45 mL (1.5 oz) of whiskey or other 80 proof distilled spirits. Thus, modest alcohol intake translates into approximately two standard size beers per day, an amount that can easily be considered social drinking. Thus, a conservative recommendation that can be unambiguously interpreted when counseling patients is that alcohol should be avoided altogether, particularly prior to antiviral treatment.
        </p>
        <p class="headingAnchor" id="H3478550975">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113060.html" rel="external">
          "Society guideline links: Hepatitis C virus infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic hepatitis C and alcoholism are common causes of liver diseases in the United States and in many other countries. (See
         <a class="local">
          'Epidemiology of hepatitis C in patients with an alcohol use disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol and HCV appear to act synergistically in promoting progression to cirrhosis and increasing the risk of hepatocellular carcinoma. (See
         <a class="local">
          'Effect of alcohol on the natural history of hepatitis C'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical studies of direct-acting antivirals required no or minimal alcohol use, so the effect of alcohol on the efficacy of such regimens is uncertain. (See
         <a class="local">
          'Effect of alcohol on treatment of hepatitis C'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A safe threshold of alcohol consumption has not been established to date. As a result, we suggest total abstinence of alcohol in patients with chronic HCV, particularly before initiation and during antiviral therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'How much alcohol is too much?'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Regev A, Jeffers LJ. Hepatitis C and alcohol. Alcohol Clin Exp Res 1999; 23:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esteban JI, Esteban R, Viladomiu L, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989; 2:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bode JC, Biermann J, Kohse KP, et al. High incidence of antibodies to hepatitis C virus in alcoholic cirrhosis: fact or fiction? Alcohol Alcohol 1991; 26:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caldwell SH, Li X, Rourk RM, et al. Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol 1993; 88:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coelho-Little ME, Jeffers LJ, Bernstein DE, et al. Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease. Alcohol Clin Exp Res 1995; 19:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parés A, Barrera JM, Caballería J, et al. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology 1990; 12:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nalpas B, Thiers V, Pol S, et al. Hepatitis C viremia and anti-HCV antibodies in alcoholics. J Hepatol 1992; 14:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Befrits R, Hedman M, Blomquist L, et al. Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease. Scand J Gastroenterol 1995; 30:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsui JI, Pletcher MJ, Vittinghoff E, et al. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. J Hepatol 2006; 44:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang JJ, Dubois F, Driss F, et al. Clinical impact of drug addiction in alcoholics. Alcohol Alcohol 1995; 30:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nalpas B, Pol S, Thépot V, et al. ESBRA 1997 Award lecture: relationship between excessive alcohol drinking and viral infections. Alcohol Alcohol 1998; 33:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbaan H, Andersson K, Eriksson S. Intravenous drug abuse--the major route of hepatitis C virus transmission among alcohol-dependent individuals? Scand J Gastroenterol 1993; 28:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brillanti S, Masci C, Siringo S, et al. Serological and histological aspects of hepatitis C virus infection in alcoholic patients. J Hepatol 1991; 13:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caldwell SH, Jeffers LJ, Ditomaso A, et al. Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am J Gastroenterol 1991; 86:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas DL. Hepatitis C epidemiology: injecting new tools in the field. Hepatology 2000; 31:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27:1730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27:1717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995; 15:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan MH, Thomas L, Byth K, et al. How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? J Gastroenterol Hepatol 1998; 13:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998; 27:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bedogni G, Miglioli L, Masutti F, et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol 2008; 103:2248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005; 3:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kayali Z, Tan S, Shinkunas L, et al. Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans. J Viral Hepat 2007; 14:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004; 39:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delarocque-Astagneau E, Roudot-Thoraval F, Campèse C, et al. Past excessive alcohol consumption: a major determinant of severe liver disease among newly referred hepatitis C virus infected patients in hepatology reference centers, France, 2001. Ann Epidemiol 2005; 15:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Said A, Williams J, Holden J, et al. The prevalence of alcohol-induced liver disease and hepatitis C and their interaction in a tertiary care setting. Clin Gastroenterol Hepatol 2004; 2:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CM, Yoon YH, Yi HY, Lucas DL. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcohol Clin Exp Res 2007; 31:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Younossi ZM, Zheng L, Stepanova M, et al. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. Aliment Pharmacol Ther 2013; 37:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamauchi M, Nakahara M, Maezawa Y, et al. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am J Gastroenterol 1993; 88:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donato F, Tagger A, Chiesa R, et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 1997; 26:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tagger A, Donato F, Ribero ML, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benvegnù L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74:2442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torbenson M, Yeh MM, Abraham SC. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis. Am J Surg Pathol 2007; 31:1410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCartney EM, Semendric L, Helbig KJ, et al. Alcohol metabolism increases the replication of hepatitis C virus and attenuates the antiviral action of interferon. J Infect Dis 2008; 198:1766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang T, Li Y, Lai JP, et al. Alcohol potentiates hepatitis C virus replicon expression. Hepatology 2003; 38:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trujillo-Murillo K, Alvarez-Martínez O, Garza-Rodríguez L, et al. Additive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activity. J Viral Hepat 2007; 14:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plumlee CR, Lazaro CA, Fausto N, Polyak SJ. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virol J 2005; 2:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand BS, Thornby J. Alcohol has no effect on hepatitis C virus replication: a meta-analysis. Gut 2005; 54:1468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolakopoulos S, Economou M, Bethanis S, et al. A single alcohol ingestion does not affect serum hepatitis C virus RNA in patients with chronic hepatitis C. Liver Int 2006; 26:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szabo G, Aloman C, Polyak SJ, et al. Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 2006; 30:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szabo G. Pathogenic interactions between alcohol and hepatitis C. Curr Gastroenterol Rep 2003; 5:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aloman C, Gehring S, Wintermeyer P, et al. Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. Gastroenterology 2007; 132:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham CS, Wells A, Edwards EM, et al. Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection. J Infect Dis 2007; 195:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolganiuc A, Kodys K, Kopasz A, et al. Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction. Alcohol Clin Exp Res 2003; 27:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigamonti C, Mottaran E, Reale E, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003; 38:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otani K, Korenaga M, Beard MR, et al. Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 2005; 128:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang T, Weinman SA. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol Hepatol 2006; 21 Suppl 3:S34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duguay L, Coutu D, Hetu C, Joly JG. Inhibition of liver regeneration by chronic alcohol administration. Gut 1982; 23:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seronello S, Sheikh MY, Choi J. Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Radic Biol Med 2007; 43:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman KE, Rouster SD, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Hepatology 1999; 30:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan DG, Bruden D, Deubner H, et al. Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease. J Infect Dis 2007; 196:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong TL, Kanel GC, Conrad A, et al. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994; 19:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchimura Y, Sata M, Kage M, et al. A histopathological study of alcoholics with chronic HCV infection: comparison with chronic hepatitis C and alcoholic liver disease. Liver 1995; 15:300.
          </a>
         </li>
         <li class="breakAll">
          HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org/full-report-view (Accessed on January 07, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamal MM, Saadi Z, Morgan TR. Alcohol and hepatitis C. Dig Dis 2005; 23:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabone M, Sidoli L, Laudi C, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002; 9:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang A, Skole K, Gautam M, et al. The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005; 22:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell M, Pauly MP, Moore CD, et al. The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan. Hepatology 2012; 56:1223.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3585 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10512322" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hepatitis C and alcohol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2569102" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hepatitis C virus antibodies among risk groups in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1652249" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : High incidence of antibodies to hepatitis C virus in alcoholic cirrhosis: fact or fiction?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8391209" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8561287" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2175291" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1380027" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hepatitis C viremia and anti-HCV antibodies in alcoholics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8578173" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16226823" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17005764" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Rate and predictors of treatment prescription for hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7538299" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical impact of drug addiction in alcoholics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9632045" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : ESBRA 1997 Award lecture: relationship between excessive alcohol drinking and viral infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7692588" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Intravenous drug abuse--the major route of hepatitis C virus transmission among alcohol-dependent individuals?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1667017" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Serological and histological aspects of hepatitis C virus infection in alcoholic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1652885" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10706576" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hepatitis C epidemiology: injecting new tools in the field.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10706569" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9121257" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9252163" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9620350" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Role of alcohol in the progression of liver disease caused by hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9620348" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7597440" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9731576" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Impact of alcohol on the histological and clinical progression of hepatitis C infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9641308" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9537428" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11177315" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10904508" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The natural history of hepatitis C virus infection: host, viral, and environmental factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18637095" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16271348" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17212639" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14999703" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Risks of a range of alcohol intake on hepatitis C-related fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16117999" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Past excessive alcohol consumption: a major determinant of severe liver disease among newly referred hepatitis C virus infected patients in hepatology reference centers, France, 2001.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15476157" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The prevalence of alcohol-induced liver disease and hepatitis C and their interaction in a tertiary care setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17250621" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23432436" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7678368" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9303486" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10328218" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9672166" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7922998" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7686879" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12395331" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17721197" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18956976" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Alcohol metabolism increases the replication of hepatitis C virus and attenuates the antiviral action of interferon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12829987" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Alcohol potentiates hepatitis C virus replicon expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17697012" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Additive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16324217" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7523270" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16162952" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Alcohol has no effect on hepatitis C virus replication: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17105584" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A single alcohol ingestion does not affect serum hepatitis C virus RNA in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16573590" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12530953" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Pathogenic interactions between alcohol and hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17258730" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17299715" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12824825" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12829985" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15633127" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16958669" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7056500" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Inhibition of liver regeneration by chronic alcohol administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17697932" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Redox regulation of hepatitis C in nonalcoholic and alcoholic liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10385665" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17570111" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7509769" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8609809" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A histopathological study of alcoholics with chronic HCV infection: comparison with chronic hepatitis C and alcoholic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8609809" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A histopathological study of alcoholics with chronic HCV infection: comparison with chronic hepatitis C and alcoholic liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8677998" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7871371" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16697724" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Alcohol use and treatment of hepatitis C virus: results of a national multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16508293" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Alcohol and hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12081606" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16197490" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22488513" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
